Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration

Abstract

Lipid Nanoparticles (LNPs) are used to deliver siRNA and COVID-19 mRNA vaccines. The main factor known to determine their delivery efficiency is the pKa of the LNP containing an ionizable lipid. Herein, we report a method that can predict the LNP pKa from the structure of the ionizable lipid. We used theoretical, NMR, fluorescent-dye binding, and electrophoretic mobility methods to comprehensively measure protonation of both the ionizable lipid and the formulated LNP. The pKa of the ionizable lipid was 2-3 units higher than the pKa of the LNP primarily due to proton solvation energy differences between the LNP and aqueous medium. We exploited these results to explain a wide range of delivery efficiencies in vitro and in vivo for intramuscular (IM) and intravascular (IV) administration of different ionizable lipids at escalating ionizable lipid-to-mRNA ratios in the LNP. In addition, we determined that more negatively charged LNPs exhibit higher off-target systemic expression of mRNA in the liver following IM administration. This undesirable systemic off-target expression of mRNA-LNP vaccines could be minimized through appropriate design of the ionizable lipid and LNP.

References 55

1. 1.

   Moderna. Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inchttps://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/ (2020).

   Not in our library

2. 2.

   BIONTECH. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | BioNTech https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine/ (2020).

   Not in our library

3. 3.

   Cullis PR, Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 2017;25:1467-1475.

   Not in our library10.1016/j.ymthe.2017.03.013

4. 4.
   How mRNA therapeutics are entering the monoclonal antibody field · 2019

   No notice
5. 5.
   Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing · 2020

   No notice
6. 6.

   Evers MJW, et al. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods. 2018;2:1700375.

   Not in our library10.1002/smtd.201700375

7. 7.

   Cheng, Q. et al. Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery and CRISPR–Cas Gene Editing. Nat. Nanotechnol. 10.1038/s41565-020-0669-6 (2020).

   Not in our library10.1038/s41565-020-0669-6

8. 8.

   Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 2016;7:319-334.

   Not in our library10.4155/tde-2016-0006

9. 9.

   Pardi N, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 2018;215:1571-1588.

   Not in our library10.1084/jem.20171450

10. 10.

    Akinc A, et al. The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019;14:1084-1087.

    Not in our library10.1038/s41565-019-0591-y

11. 11.

    Gruner SM, Cullis PR, Hope MJ, Tilcock CPS. Lipid polymorphism: the molecular basis of nonbilayer phases. Annu. Rev. Biophys. Biophys. Chem. 1985;14:211-238.

    Not in our library10.1146/annurev.bb.14.060185.001235

12. 12.

    Witzigmann D, et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv. Drug Deliv. Rev. 2020.

    Not in our library10.1016/j.addr.2020.06.026

13. 13.

    Hassett KJ, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids. 2019;15:1-11.

    Not in our library10.1016/j.omtn.2019.01.013

14. 14.

    Moderna. mRNA-1273-P301-Protocolhttps://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf (2020).

    Not in our library

15. 15.

    Pfizer. Pfizer-BioNTech Covid-19 Vaccine FDA EAU Letter of Authorizationhttps://www.fda.gov/media/144412/download (2020).

    Not in our library

16. 16.

    Kranz LM, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401.

    Not in our library10.1038/nature18300

17. 17.

    Bahl K, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 2017;25:1316-1327.

    Not in our library10.1016/j.ymthe.2017.03.035

18. 18.

    Hajj KA, et al. A potent branched-tail lipid nanoparticle enables multiplexed mRNA delivery and gene editing in vivo. Nano Lett. 2020;20:5167-5175.

    Not in our library10.1021/acs.nanolett.0c00596

19. 19.

    Pardi N, et al. Expression kinetics of nucleoside-modified mrna delivered in lipid nanoparticles to mice by various routes. J. Control. Release. 2015;217:345-351.

    Not in our library10.1016/j.jconrel.2015.08.007

20. 20.

    Akinc A, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 2010;18:1357-1364.

    Not in our library10.1038/mt.2010.85

21. 21.

    Walsh, E. E. et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv. 10.1101/2020.08.17.20176651 (2020).

    Not in our library

22. 22.

    Anderson EJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 2020;383:2427-2438.

    Not in our library10.1056/nejmoa2028436

23. 23.

    Jenne CN, Kubes P. Immune surveillance by the liver. Nat. Immunol. 2013;14:996-1006.

    Not in our library10.1038/ni.2691

24. 24.
    Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** · 2012

    No notice
25. 25.

    Semple SC, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta BBA - Biomembr. 2001;1510:152-166.

    Not in our library10.1016/s0005-2736(00)00343-6

26. 26.

    Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release. 2005;107:276-287.

    Not in our library10.1016/j.jconrel.2005.06.014

27. 27.

    Oregioni A, Stieglitz B, Kelly G, Rittinger K, Frenkiel T. Determination of the PK a of the N-Terminal Amino Group of Ubiquitin by NMR. Sci. Rep. 2017;7:1-8.

    Not in our library10.1038/srep43748

28. 28.

    Katchalsky A, Spitnik P. Potentiometric titrations of polymethacrylic acid. J. Polym. Sci. 1947;2:432-446.

    Not in our library10.1002/pol.1947.120020409

29. 29.

    Filion D, Lavertu M, Buschmann MD. Ionization and solubility of chitosan solutions related to thermosensitive chitosan/glycerol-phosphate systems. Biomacromolecules. 2007;8:3224-3234.

    Not in our library10.1021/bm700520m

30. 30.

    Yanez Arteta M, et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA. 2018;115:E3351-E3360.

    Not in our library10.1073/pnas.1720542115

31. 31.

    Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 2020.

    Not in our library10.1021/acs.nanolett.0c01386

32. 32.

    Madden, T. D., Tam, Y. K. C., Barbosa, C. J., Mui, B. Lamellar Lipid Nanoparticles. WO2019089828A1. 9 May 2019.

    Not in our library

33. 33.

    Kulkarni JA, et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and SiRNA. ACS Nano. 2018;12:4787-4795.

    Not in our library10.1021/acsnano.8b01516

34. 34.

    Kulkarni JA, et al. Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. Nanoscale. 2019;11:9023-9031.

    Not in our library10.1039/c9nr02004g

35. 35.

    Fenton OS, et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 2017;29:1606944.

    Not in our library10.1002/adma.201606944

36. 36.

    Semple SC, et al. Rational design of cationic lipids for SiRNA delivery. Nat. Biotechnol. 2010;28:172-176.

    Not in our library10.1038/nbt.1602

37. 37.

    Soliman OY, Alameh MG, De Cresenzo G, Buschmann MD, Lavertu M. Efficiency of chitosan/hyaluronan-based mRNA delivery systems in vitro: influence of composition and structure. J. Pharm. Sci. 2020;109:1581-1593.

    Not in our library10.1016/j.xphs.2019.12.020

38. 38.

    Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl Acad. Sci. USA. 1996;93:12349-12354.

    Not in our library10.1073/pnas.93.22.12349

39. 39.

    Yan X, et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem. Biophys. Res. Commun. 2005;328:57-62.

    Not in our library10.1016/j.bbrc.2004.12.137

40. 40.

    Weaver, J. C. & Schoenbach, K. H. Biodielectrics. IEEE Transactions on Dielectrics and Electrical Insulation. Vol. 10, p. 715–716 (IEEE, 2003)..

    Not in our library

41. 41.

    Hajj KA, et al. Branched-tail lipid nanoparticles potently deliver mRNA in vivo due to enhanced ionization at endosomal PH. Small. 2019;15:1805097.

    Not in our library10.1002/smll.201805097

42. 42.
    A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA · 2019

    No notice
43. 43.

    Zhang J, Fan H, Levorse DA, Crocker LS. Ionization behavior of amino lipids for SiRNA delivery: determination of ionization constants, SAR, and the impact of lipid PKa on cationic lipid−biomembrane interactions. Langmuir. 2011;27:1907-1914.

    Not in our library10.1021/la104590k

44. 44.

    Sabnis S, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 2018;26:1509-1519.

    Not in our library10.1016/j.ymthe.2018.03.010

45. 45.

    Li X, et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat. Methods. 2013;10:584-590.

    Not in our library10.1038/nmeth.2472

46. 46.

    Kumar, P., Elsaidi, H., Wiebe, L. I., Weinfeld, M. & Ricardo, C. L. Bioreductively-Activated Compounds, Their Prodrugs, Radiopharmaceuticals, the Compositions, and Their Applications in Multimodal Theranostic Management of Hypoxia Diseases Including Cancer. WO2019056098A1. 28 March 2019.

    Not in our library

47. 47.

    Smith PG, Dhanuka VV, Hwang HS, Lim KT, Johnston KP. Tertiary amine esters for carbon dioxide based emulsions. Ind. Eng. Chem. Res. 2007;46:2473-2480.

    Not in our library10.1021/ie060934h

48. 48.

    Bennett, M. J. et al. New (S)-2-(Cyclopentanecarbonyl-Amino)-3-Phenyl-Propionic Acid Compounds Are Very Late Antigen-4 Inhibitors, Useful for e.g. Treating Cancer or Inflammatory Diseases. US 20130079383 A1 (2013).

    Not in our library

49. 49.

    Hu, X. et al. Propylene Glycol Amine Derivative of Cationic Liposome Nanoparticle to Deliver Nucleic Acid Comprises Iodized 2,3-Dialkoxyl-1-(N,N,N-Trimethyl)Propylamine, or Brominated 2,3-Dialkoxyl-1-(N,N-Dimethyl-N-(2-Ethoxy)Propylamine Nanoparticle. CN 102525926 A (2011).

    Not in our library

50. 50.

    Felgner PL, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA. 1987;84:7413-7417.

    Not in our library10.1073/pnas.84.21.7413

51. 51.

    Sartoru, M. et al. New Dimethylamino-Alkanoyloxy-Bis-((Tetradec-9-Enoyloxy)Methyl)Propyl Tetradec-9-Enoate Derivative Useful in Composition for Introducing Nucleic Acid e.g. Small Interfering RNA for Treating Disease e.g. Anemia, Psoriasis, and Lung Cancer. WO2019131839-A1 (2019).

    Not in our library

52. 52.

    Liang X, et al. Design and synthesis of lipidic organoalkoxysilanes for the self-assembly of liposomal nanohybrid cerasomes with controlled drug release properties. Chem. Eur. J. 2013;19:16113-16121.

    Not in our library10.1002/chem.201302518

53. 53.

    Baryza, J. et al Lipids, Lipid Compositions, and Methods of Using Them. WO2011076807A2. 30 June 2011.

    Not in our library

54. 54.

    Dande, P. A. et al. Cationic Lipids and Uses Thereof. US20100055169A1. 4 March 2010.

    Not in our library

55. 55.

    Baryshnikova OK, Williams TC, Sykes BD. Internal PH indicators for biomolecular NMR. J. Biomol. NMR. 2008;41:5-7.

    Not in our library10.1007/s10858-008-9234-6

Cited by papers we hold 1

• Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications · 2024
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.